azd-0328

Small moleculeexperimental

Clinical trial activity

5 trials · 12 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Nov 1, 2007 (NCT00687141)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

c1cnc2c(c1)C[C@@]1(CN3CCC1CC3)O2
Mol. weight
216.28 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • azd0328
  • azd0328
  • azd0328
  • azd0328
  • azd 0328
  • azd-0328
  • azd-0328
  • azd-0328
  • azd-0328
  • spiro(1-azabicyclo(2.2.2)octane-3,2'(3h)-furo(2,3-b)pyridine)

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04810104Phase 2Apr 30, 2021AstraZeneca, European Commission, Masaryk University, Michael J. Fox Foundation for Parkinson's Research, Norges Parkinsonforbund, Norway, PARKINSONS UK, Stichting Lygature, University of Exeter, University of London, University of Stavanger
NCT00752830Phase 1Sep 1, 2008AstraZeneca
NCT00738959Phase 1Jun 1, 2008AstraZeneca, Richmond Pharmacology
NCT00669903Phase 2Apr 1, 2008AstraZeneca
NCT00687141Phase 1Nov 1, 2007AstraZeneca, IQVIA
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AstraZenecaFor profit5422007
European CommissionGovernment1012021
IQVIAFor profit1012007
Masaryk UniversityAcademic/Hospital1012021
Michael J. Fox Foundation for Parkinson's ResearchAcademic/Hospital1012021
Norges Parkinsonforbund, NorwayAcademic/Hospital1012021
PARKINSONS UKAcademic/Hospital1012021
Richmond PharmacologyFor profit1012008
Stichting LygatureAcademic/Hospital1012021
University of ExeterAcademic/Hospital1012021
University of LondonAcademic/Hospital1112021
University of StavangerAcademic/Hospital1012021
12 organizations
Page 1 / 1